Rapport Therapeutics, Inc.
RAPP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002012593
In the last 90 days, Rapport Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 160 institutions reported holding it in 13F filings for Q2 2026, worth $2.13B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $7.55M in total
- 10
- 13F holdersQ2 2026, +16 vs. previous quarter
- 160
- 13F valueReported value at the end of Q2 2026
- $2.13B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding RAPP, Q2 2026
No superinvestor reported holding RAPP at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Rapport Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 (view filing)4:05 PM ET | Sep 23 | 1 day | Ceesay AbrahamChief Executive Officer | SSale | −2.21K | $39.17 | −$86.6K | −0.5%456.8K after | 3 lots10b5-1 |
| Sep 9, 2026 (view filing)4:05 PM ET | Sep 8 | 1 day | Ceesay AbrahamChief Executive Officer | SSale | −8.21K | $45.61 | −$374.5K | −1.8%459.0K after | 2 lots10b5-1 |
| Aug 26, 2026 (view filing)4:05 PM ET | Aug 25 | 1 day | Ceesay AbrahamChief Executive Officer | SSale | −18.9K | $49.57 | −$938.0K | −3.9%467.2K after | 10b5-1 |
| Aug 26, 2026 (view filing)4:00 PM ET | Aug 24-25 | 2 days | Yeleswaram KrishnaswamyChief Development Officer | SSale | −50.2K | $50.47 | −$2.53M | −20.4%195.9K after | 3 lots10b5-1 |
| Aug 20, 2026 (view filing)4:09 PM ET | Aug 19 | 1 day | Yeleswaram KrishnaswamyChief Development Officer | SSale | −404 | $49.90 | −$20.2K | −0.2%246.0K after | 10b5-1 |
| Aug 12, 2026 (view filing)4:35 PM ET | Aug 10-11 | 2 days | Ceesay AbrahamChief Executive Officer | SSale | −51.5K | $47.25 | −$2.43M | −9.6%486.1K after | 5 lots10b5-1 |
| Jul 29, 2026 (view filing)4:05 PM ET | Jul 27 | 2 days | Ceesay AbrahamChief Executive Officer | SSale | −2.21K | $42.11 | −$93.1K | −0.4%537.6K after | 2 lots10b5-1 |
| Jul 15, 2026 (view filing)4:15 PM ET | Jul 14 | 1 day | Ceesay AbrahamChief Executive Officer | SSale | −8.21K | $40.00 | −$328.4K | −1.5%539.8K after | 2 lots10b5-1 |
| Jul 1, 2026 (view filing)4:10 PM ET | Jun 30 | 1 day | Gault CherylChief Operating Officer | SSale | −10.0K | $41.58 | −$415.8K | −6.3%149.9K after | 4 lots10b5-1 |
| Jul 1, 2026 (view filing)4:05 PM ET | Jun 29 | 2 days | Ceesay AbrahamChief Executive Officer | SSale | −8.22K | $39.83 | −$327.4K | −1.5%548.0K after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Rapport Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 7,172,894 | $298.9M | 0.01% | +3,955+0.1% | Added |
| TRV GP V, LLC | 6,280,525 | $261.7M | 52.53% | −854,708−12.0% | Reduced |
| ARCH Venture Management, LLC | 3,728,738 | $155.4M | 14.12% | 00.0% | Unchanged |
| Capital International Investors | 2,921,958 | $121.8M | 0.03% | −176,015−5.7% | Reduced |
| Goldman Sachs Group Inc | 2,910,449 | $121.3M | 0.01% | −31,802−1.1% | Reduced |
| BlackRock, Inc. | 2,699,786 | $112.5M | 0.00% | +193,831+7.7% | Added |
| Cormorant Asset Management, LP | 2,657,521 | $110.7M | 5.67% | −300,000−10.1% | Reduced |
| Sofinnova Investments, Inc. | 1,904,408 | $79.4M | 4.24% | 00.0% | Unchanged |
| Johnson & Johnson | 1,784,517 | $74.4M | 9.31% | 00.0% | Unchanged |
| Polar Capital Holdings Plc | 1,608,514 | $67.0M | 0.19% | −33,947−2.1% | Reduced |